Skip to main content

Table 7 Responsiveness of measures over time to perceived benefit/harm; baseline to 4 months

From: An empirical evaluation of the SF-12, SF-6D, EQ-5D and Michigan Hand Outcome Questionnaire in patients with rheumatoid arthritis of the hand

  n T0 T4 Δ (95% CI) SRM (95% CI) ES (95% CI)
MHQ
 Benefit 303 51.91 57.86 5.95 (2.75 to 9.15) 0.21 (-1.70 to 3.12) 0.29 (-1.61 to 2.21)
 No benefit 116 49.34 49.14 -0.2 (-3.46 to 3.06) -0.01 (-2.98 to 2.96) -0.02 (-2.98 to 2.95)
 Harm 11 45.93 48.37 2.44 (-11.61 to 16.48) 0.10 (-7.40 to 7.61) 0.14 (-7.36 to 7.65)
EQ-5D (utility)
 Benefit 303 0.59 0.63 0.04 (0.00 to 0.08) 0.11 (0.08 to 0.14) 0.15 (0.13 to 0.18)
 No benefit 116 0.59 0.57 -0.02 (-0.09 to 0.05) -0.05 (-0.09 to 0.00) -0.07 (-0.12 to -0.02)
 Harm 11 0.55 0.59 0.04 (-0.23 to 0.31) 0.09 (-0.13 to 0.31) 0.13 (-0.09 to 0.35)
EQ-5D (VAS)
 Benefit 303 68.92 71.99 3.07 (0.32 to 5.82) 0.13 (-1.85 to 2.10) 0.18 (-1.80 to 2.15)
 No benefit 116 65.77 63.09 -2.68 (-7.93 to 2.57) -0.09 (-3.72 to 3.53) -0.13 (-3.75 to 4.49)
 Harm 11 61.18 61.81 0.63 (-18.12 to 19.38) 0.02 (-15.19 to 15.23) 0.03 (-15.18 to 15.23)
SF-12 (PCS)
 Benefit 303 34.02 35.27 1.25 (-0.64 to 3.14) 0.07 (-1.16 to 1.32) 0.11 (-1.14 to 1.35)
 No benefit 116 32.85 33.59 0.74 (-1.95 to 3.43) 0.05 (-1.94 to 2.04) 0.07 (-1.92 to 2.06)
 Harm 11 27.23 29.06 1.83 (-11.40 to 15.06) 0.08 (-9.47 to 9.63) 0.12 (-9.43 to 9.66)
SF-12 (MCS)
 Benefit 303 48.07 47.85 -0.22 (-2.39 to 1.96) -0.01 (-1.46 to 1.44) -0.02 (-1.47 to 1.43)
 No benefit 116 47.45 47.93 0.48 (-2.89 to 3.85) 0.03 (-2.45 to 2.50) 0.04 (-2.43 to 2.51)
 Harm 11 35.9 33.66 -2.24 (-19.75 to 15.27) -0.08 (-12.62 to 12.46) -0.11 (-12.64 to 12.43)
SF-6D
 Benefit 303 0.65 0.66 0.01 (-0.01 to 0.03) 0.05 (0.03 to 0.06) 0.06 (0.05 to 0.08)
 No benefit 116 0.63 0.64 0.01 (-0.03 to 0.05) 0.05 (0.02 to 0.08) 0.07 (0.04 to 0.10)
 Harm 11 0.61 0.52 -0.09 (-0.24 to 0.06) -0.36 (-0.45 to -0.27) -0.51 (-0.06 to -0.04)